<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17 PATIENT COUNSELING INFORMATION<BR>               <BR>                  Patients should be advised to contact their physician if they experience any adverse reactions to Carisoprodol.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.1 	Sedation<BR>                     <BR>                        Patients should be advised that Carisoprodol may cause drowsiness and/or dizziness, and has been associated with motor vehicle accidents.  Patients should be advised to avoid taking Carisoprodol before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery [see Warnings and Precautions (5.1)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.2 	Avoidance of Alcohol and Other CNS Depressants<BR>                     <BR>                        Patients should be advised to avoid alcoholic beverages while taking Carisoprodol and to check with their doctor before taking other CNS depressants such as benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, or other sedatives  [see Warnings and Precautions (5.1)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.3 	Carisoprodol Should Only Be Used for Short-Term Treatment<BR>                     <BR>                        Patients should be advised that treatment with Carisoprodol should be limited to acute use (up to two or three weeks) for the relief of acute, musculoskeletal discomfort. In the post-marketing experience with Carisoprodol, cases of dependence, withdrawal, and abuse have been reported with prolonged use.  If the musculoskeletal symptoms still persist, patients should contact their healthcare provider for further evaluation.<BR>                        Manufactured by:<BR>									<BR>Meda Pharmaceuticals Inc.<BR>									<BR>Decatur, IL 62525<BR>									<BR>For:<BR>									<BR>Wallace Pharmaceuticals Inc.<BR>									<BR>Somerset, NJ 08873-4120<BR>								<BR>                        WALLACE<BR>PHARMACEUTICALS™<BR>                        IN-5901-05     Rev. 1/2013<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>